lactic acid has been researched along with Leishmaniasis, Visceral in 9 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oleanolic acid (OA) has low aqueous solubility and low permeability, which results poor bioavailability." | 1.43 | Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis. ( Bera, T; Ghosh, S; Kar, N, 2016) |
| "Treatment with artemisinin-loaded nanoparticles significantly reduced the number of amastigotes per macrophage and percent infected macrophages ex vivo compared to free artemisinin." | 1.40 | A new approach for the delivery of artemisinin: formulation, characterization, and ex-vivo antileishmanial studies. ( Afrin, F; Chattopadhyay, AP; Chouhan, G; Dasgupta, AK; Islamuddin, M; Want, MY, 2014) |
| "Amphotericin B was incorporated into poly(D, L-lactide-co-glycolide) nanoparticles, biodegradable drug carriers, to allow specific targeting inside the cell." | 1.29 | In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. ( Benoit, JP; Monjour, L; Venier-Julienne, MC; Vouldoukis, I, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Want, MY | 1 |
| Islamuddin, M | 1 |
| Chouhan, G | 1 |
| Dasgupta, AK | 1 |
| Chattopadhyay, AP | 1 |
| Afrin, F | 1 |
| Marín, C | 1 |
| Ramírez-Macías, I | 1 |
| Rosales, MJ | 1 |
| Muro, B | 1 |
| Reviriego, F | 1 |
| Navarro, P | 1 |
| Arán, VJ | 1 |
| Sánchez-Moreno, M | 2 |
| Kumar, R | 1 |
| Sahoo, GC | 1 |
| Pandey, K | 1 |
| Das, VNR | 1 |
| Topno, RK | 1 |
| Ansari, MY | 1 |
| Rana, S | 1 |
| Das, P | 1 |
| Ghosh, S | 1 |
| Kar, N | 1 |
| Bera, T | 1 |
| Costa Lima, SA | 1 |
| Resende, M | 1 |
| Silvestre, R | 1 |
| Tavares, J | 1 |
| Ouaissi, A | 1 |
| Lin, PK | 1 |
| Cordeiro-da-Silva, A | 1 |
| Tyagi, R | 1 |
| Lala, S | 1 |
| Verma, AK | 1 |
| Nandy, AK | 1 |
| Mahato, SB | 1 |
| Maitra, A | 1 |
| Basu, MK | 1 |
| Sánchez-Brunete, JA | 1 |
| Dea, MA | 1 |
| Rama, S | 1 |
| Bolás, F | 1 |
| Alunda, JM | 1 |
| Torrado-Santiago, S | 1 |
| Torrado, JJ | 1 |
| Venier-Julienne, MC | 1 |
| Vouldoukis, I | 1 |
| Monjour, L | 1 |
| Benoit, JP | 1 |
| Mesa, C | 1 |
| Rodriguez-Cabezas, N | 1 |
| Castilla, JJ | 1 |
| Moraleda-Lindez, V | 1 |
| Barbe, J | 1 |
| Osuna, A | 1 |
9 other studies available for lactic acid and Leishmaniasis, Visceral
| Article | Year |
|---|---|
A new approach for the delivery of artemisinin: formulation, characterization, and ex-vivo antileishmanial studies.
Topics: Animals; Antiprotozoal Agents; Artemisinins; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Con | 2014 |
In vitro leishmanicidal activity of 1,3-disubstituted 5-nitroindazoles.
Topics: Acetates; Alanine; Animals; Antiprotozoal Agents; Glycine; In Vitro Techniques; Indazoles; Lactic Ac | 2015 |
Development of PLGA-PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis.
Topics: Animals; Cricetinae; Drug Delivery Systems; Lactic Acid; Leishmania donovani; Leishmaniasis, Viscera | 2016 |
Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis.
Topics: Animals; Drug Carriers; Drug Evaluation, Preclinical; Female; Inhibitory Concentration 50; Lactic Ac | 2016 |
Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies.
Topics: Animals; Antiprotozoal Agents; Cell Line; Drug Carriers; Humans; Lactic Acid; Leishmania donovani; L | 2012 |
Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis.
Topics: Animals; Antiparasitic Agents; Blood Urea Nitrogen; Chemical and Drug Induced Liver Injury; Chemistr | 2005 |
Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B.
Topics: Albumins; Amphotericin B; Animals; Antigens, Protozoan; Antiprotozoal Agents; Cricetinae; Drug Carri | 2005 |
In vitro study of the anti-leishmanial activity of biodegradable nanoparticles.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Biocompatible Materials; Cell Survival; Drug Carriers | 1995 |
In vitro and in vivo activities of three acridine thioethers against Leishmania donovani.
Topics: Acetates; Acridines; Animals; Antiprotozoal Agents; Cell Division; Cell Line; Dose-Response Relation | 2002 |